Intervention strategies and agents mediating the prevention of xenorejection

Annals of the New York Academy of Sciences

Volumn 1056, Issue , 2005, Pages 123-143

  Ghebremariam, Yohannes T ^a   Smith, Scott A ^a,b   Anderson, J B ^b   Kahn, D ^a   Kotwal, Girish J ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b University of Louisville School of Medicine   (United States)

Author keywords

Complement; Hyperacute rejection; Inflammation; Modulation; Organ transplantation; VCP; Xenorejection

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; ANTIBODY; CD59 ANTIGEN; COBROTOXIN; COMPLEMENT; DECAY ACCELERATING FACTOR; UNCLASSIFIED DRUG; VACCINE; VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN; VIRUS PROTEIN;

ALLOTRANSPLANTATION; CELL TRANSPLANTATION; COMPLEMENT ACTIVATION; CONFERENCE PAPER; DOWN REGULATION; DRUG DESIGN; DRUG SAFETY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNE SYSTEM; IMMUNOMODULATION; NONHUMAN; ORGAN TRANSPLANTATION; PHYLOGENY; PLASMAPHERESIS; SWINE; TAXONOMY; TISSUE TRANSPLANTATION; TRANSGENIC ANIMAL; VASCULAR ENDOTHELIUM; XENOGRAFT; XENOTRANSPLANTATION;

ANIMALIA; SUS SCROFA; VACCINIA VIRUS;

EID: 29744469158     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1352.028     Document Type: Conference Paper

References (103)

1. MICHLER, R.E. 1996. Xenotransplantation: risks, clinical potential, and future prospects. Emerging Infect. Dis. 2: 64-70.
2. COOPER, D.K.C. 1993. Xenografting: how great is the clinical need? Xenotransplantation 1: 25-26.
3. PLATT, J.L. et al. 1990. Transplantation of discordant xenografts: a review of progress. Immunol. Today 11: 450-457.
4. COOPER, D.K.C., B. GOLLACKNER, C. KNOSALLA & K. TERANISHI. 2002. Xenotransplantation - how far have we come? Transplant. Immunol. 9: 251-256.
5. WANG, X.M., G. CHEN, S. CHEN, et al. 2001. A novel model of pig-to-monkey kidney xenotransplantation. Transplant. Proc. 33: 3859.
6. GODDARD, M.J., J.J. DUNNING, J. HORSLEY, et al. 2002. Histopathology of Cardiac xenograft rejection in the pig-to-baboon model. J. Heart Lung Transplant. 21: 474-484.
7. GROTH, C.G., O. KORSGREN, A. TIBELL, et al. 1994. Transplantation of porcine fetal pancreas to diabetic patients. Lancet 344: 1402-1404.
8. AEBISCHER, P., M. SCHLUEP, N. DÉGLON, et al. 1996. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat. Med. 2: 696-699.
9. RAM, Z. et al. 1997. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. 3: 1354-1361.
10. AEBISCHER, P., A.F. HOTTINGER & N. DÉGLON. 1999. Cellular xenotransplantation. Nat. Med. 5: 852.
11. DEACON, T., J. SCHUMACHER, J. DINSMORE, et al. 1997. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat. Med. 3: 350-353.
12. LEHRMAN, S. 1995. AIDS patient given baboon bone marrow. Nature 378: 756.
13. RELF, M.V. 1996. Xenotransplantation of baboon bone marrow cells: a historical review of the protocols as a possible treatment modality for HIV/AIDS. J. Assoc. Nurses AIDS Care 7: 27-35.
14. OHNO, K., L.R. NELSON, K. MITOOKA & W.M. BOURNE. 2002. Transplantation of cryopreserved human corneas in a xenograft model. Cryobiology 44: 142-149.
15. NICKOLOFF, B.J. & F.O. NESTLE. 2004. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 113: 1664-1675.
16. US guidelines on xenotransplantation. 1999. Nat. Med. 5: 465.
17. BUTLER, D. 1999. Europe is urged to hold back on xenotransplant clinical trials. Nature 397: 281-282.
18. REEMTSMA. K. 1991. Xenotransplantation: a brief history of clinical experiences: 1900-1965: early attempts at renal xenografting. In Xenotransplantation: The Transplantation of Organs and Tissues Between Species. D.K.C. Cooper, E. Kemp, K. Reemtsma & D.J.G. White, Eds. :9-22. Springer-Verlag. Berlin, Heidelberg.
19. COOPER, D.K.C. & Y. YE. 1991. Experience with clinical heart xenotransplantation. In Xenotransplantation: The Transplantation of Organs and Tissues Between Species. D.K.C. Cooper, E. Kemp, K. Reemtsma & D.J.G. White, Eds. :541-557. Springer-Verlag. Berlin, Heidelberg.
20. BARNARD, C.N., A. WOLPOWITZ & J.G. LOSMAN. 1977. Heterotopic cardiac transplantation with a xenograft for assistance of the left heart in cardiogenic shock after cardiopulmonary bypass. S. Afr. Med. J. 52: 1035-1038.
21. BACH, F.H. & H. AUCHINCLOSS. 1995. Transplantation Immunology. New York. Wiley-Liss. Xi, 409.
22. THE RIGHT REVEREND LORD JOHN HABGOOD, A.G. SPAGNOLO, E. SGRECCIA & A.S. DAAR. 1997. Religious views on organ and tissue donation. In Organ and Tissue Donation for Transplantation. Jeremy R. Chapman, Mark Deierhoi & Celia Wight, Eds. :23-33. Arnold, a member of the Hodder Headline Group.
23. LAI, L., D. KOLBER-SIMONDS, K.-W. PARK, et al. 2002. Production of α-1,3-Galactosyl-transferase knockout pigs by nuclear transfer cloning. Science 295: 1089-1092.
24. PRATHER, R.S., R.J. HAWLEY, R.J. CARTER, et al. 2003. Transgenic swine for biomedicine and agriculture. Theriogenology 59: 115-123.
25. VAN DENDEREN, B.J. et al. 1997. Combination of decay-accelerating factor expression and alpha 1,3-galactosyltransferase knockout affords added protection from human complement-mediated injury. Transplantation 64: 882-888.
26. GALILI, U. et al. 1988. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J. Biol. Chem. 263: 17755-17762.
27. GALILI, U. 1998. Anti-Gal antibody prevents xenotransplantation. Sci. Med. 5: 28-37.
28. RYAN, U.S. 1995. Complement inhibitory therapeutics and xenotransplantation. Nat. Med. 1: 967-968.
29. COOPER, D.K.C. 1991. Xenotransplantation: The Transplantation of Organs and Tissues between Species. Berlin, New York. Springer-Verlag.
30. LUO, Y. et al. 1998. Comparative histopathology of hepatic allografts and xenografts in the nonhuman primate. Xenotransplantation 5: 197-206.
31. ANDERSON, J.B., S.A. SMITH, R. VAN WIJK, et al. 2003. Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation. Transplant Immunol. 11:, 129-135.
32. MIYAGAWA, S. et al. 1988. The mechanism of discordant xenograft rejection. Transplantation 46: 825-830.
33. GAMBIEZ, L., E. SALAME, C. CHEREAU, et al. 1992. Natural IgM play a major role in hyperacute rejection of discordant heart xenografts. Transplant. Proc. 24: 441-442.
34. GAMBIEZ, L., E. SALAME, C. CHEREAU, et al. 1992. The role of natural IgM in the hyperacute rejection of discordant heart xenografts. Transplantation 54: 577-583.
35. GALILI, U. et al. 1988. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect. Immun. 56: 1730-1737.
36. BRACY, J.L., D.H. SACHS & J. IACOMINI. 1998. Inhibition of xenoreactive natural antibody production by retroviral gene therapy. Science 281: 1845-1847.
37. GALILI, U. et al. 1984. A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J. Exp. Med. 160: 1519-1531.
38. GALILI, U. et al. 1987. Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1-3Gal epitope in primates. Proc. Natl. Acad. Sci. USA 84: 1369-1373.
39. GALILI, U., C.R. GREGORY & R.E. MORRIS. 1995. Contribution of anti-Gal to primate and human IgG binding to porcine endothelial cells. Transplantation 60: 210-213.
40. PLATT, J.L. & F.H. BACH. 1991. Mechanisms of tissue injury in hyperacute xenograft rejection: a model of hyperacute xenograft rejection. In Xenotransplantation: The Transplantation of Organs and Tissues between Species. D.K.C. Cooper, E. Kemp, K. Reemtsma & D.J.G. White, Eds. :69-79. Springer-Verlag. Berlin, Heidelberg.
41. PLATT, J.L. et al. 1990. Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J. Exp. Med. 171: 1363-1368.
42. IHRCKE, N.S. & J.L. PLATT. 1996. Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell-surface molecules. J. Cell Physiol. 168: 625-637.
43. PLATT, J.L. et al. 1991. The role of C5a and antibody in the release of heparan sulfate from endothelial cells. Eur. J. Immunol. 21: 2887-2890.
44. SAADI, S. & J.L. PLATT. 1995. Transient perturbation of endothelial integrity induced by natural antibodies and complement. J. Exp. Med. 181: 21-31.
45. JANSON, T.L., H. STORMORKEN & H. PRYDZ. 1984. Species specificity of tissue thromboplastin. Haemostasis 14: 440-444.
46. JURD, K.M., R.V. GIBBS & B.J. HUNT. 1996. Activation of human prothrombin by porcine aortic endothelial cells - a potential barrier to pig to human xenotransplantation. Blood Coagul. Fibrinolysis 7: 336-343.
47. JURD, K.M., R.V. GIBBS & B.J. HUNT. 1996. Activation of human prothrombin by porcine endothelium. Transplant. Proc. 28: 610.
48. PARETI, F.I. et al. 1992. Interaction of porcine von Willebrand factor with the platelet glycoproteins Ib and IIb/IIIa complex. Br. J. Haematol. 82: 81-86.
49. HAISCH, C.E. et al. 1990. The vascular endothelial cell is central to xenogeneic immune reactivity. Surgery 108: 306-311.
50. Rose, A.G. et al. 1991. Histopathology of hyperacute rejection of the heart: experimental and clinical observations in allografts and xenografts. J. Heart Lung Transplant. 10: 223-234.
51. ROSE, A.G. & D.K.C. COOPER. 1996. A histopathologic grading system of hyperacute (humoral, antibody-mediated) cardiac xenograft and allocraft rejection. J. Heart Lung Transplant. 15: 804-817.
52. KOBAYASHI, T. et al. 1997. Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy. Transplantation 64: 1255-1261.
53. LEVENTHAL, J.R., A.P. DALMASSO, J.W. CROMWELL, et al. 1993. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 55: 857-866.
54. BACH, F.H., S.C. ROBSON, H. WINKER, et al. 1995. Barriers to xenotransplantation. Nat. Med. 1: 869-873.
55. nd Ed. Berlin, New York. Springer. Xxxiv, 854.
56. BACH, F.H., S.C. ROBSON, C. FERRAN, et al. 1995. Xenotransplantation: endothelial cell activation and beyond. Transplant. Proc. 27: 77-79.
57. BACH, F.H. et al. 1996. Delayed xenograft rejection. Immunol. Today 17: 379-384.
58. BACH, F.H. et al. 1997. Modification of vascular responses in xenotransplantation: inflammation and apoptosis. Nat. Med. 3: 944-948.
59. KOZLOWSKI, T. et al. 1999. Porcine kidney and heart transplantation in baboons undergoing a tolerance induction regimen and antibody adsorption. Transplantation 67: 18-30.
60. HANCOCK, W.W. & F.H. Bach. 1994. The immunology of discordant xenotransplantation. Xenotransplantation 2: 68-77.
61. SEOW, J. 2003. Clinical xenotransplantation. The Lancet 362: 1421-1422.
62. BACH, F.H., J.L. PLATT & D.K.C. COOPER. 1991. Accommodation: the role of natural antibody and complement in discordant xenograft rejection: methods of removal of preformed natural antibodies. In Xenotransplantation: The Transplantation of Organs and Tissues Between Species. D.K.C.E. Kemp, K. Reemtsma & D.J.G. White, Eds. :81-99. Springer-Verlag. Berlin, Heidelberg.
63. REDING, R., S. ff. H. DAVIES, D.J.G. WHITE, et al. 1989. Effect of plasma exchange on guinea pig-to-rat heart xenografts. Transplant. Proc. 21: 534-536.
64. MAJADO, M.J. et al. 2002. ABO system and blood crossmatch study in baboons: importance of designing a primate blood bank for orthotopic pig-to-baboon liver xenotransplantation. Transplant. Proc. 34: 327-328.
65. ASANO, M., S.R. Gundry, H. Izutani, et al. 2003. Baboons undergoing orthotopic concordant cardiac xenotransplantation surviving more than 300 days: effect of immunosuppressive regimen. J. Thoracic Cardiovasc. Surg. 125: 60-70.
66. TUSO, P.J., D.V. CARMER, C. YASUNAGA, et al. 1993. Removal of natural human xenoantibodies to pig vascular endothelium by perfusion of blood through pig kidneys and livers. Transplantation 55: 1375-1378.
67. DIAMOND, L.E. et al. 1996. Characterization of transgenic pigs expressing functionally active CD59 on cardiac endothelium. Transplantation 61: 121-129.
68. LANGFORD, G.A., N. YANNOUTSOS, E. COZZI, et al. 1994. Production of pigs transgenic for human decay accelerating factor. Transplant. Proc. 26: 1400-1401.
69. COZZI, E. & D.J.G. WHITE. 1995 The generation of transgenic pigs as potential organ donors for humans. Nat. Med. 1: 964-966.
70. ROSENGARD, A.M., N.R.B. CARRY, G.A. Langford, et al. 1995. Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs. Transplantation 59: 1325-1333.
71. BRANDL, U. et al. 2003. 25 days of baboons after orthotopic xenotransplantation of hDAF transgenic pig hearts using a moderate immunosuppression (Abstr). J. Heart Lung Transplant. 22: S100-S101.
72. RAMIREZ, P. et al. 2002. Transgenic pig-to-baboon liver xenotransplantation: clinical, biochemical, and immunologic pattern of delayed acute vascular rejection. Transplant. Proc. 34: 319-320.
73. MCCURRY, K.R. et al. 1995. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat. Med. 1: 423-427.
74. SCHMOECKEL, M. et al. 1997. Transgenic human decay accelerating factor makes normal pigs function as a concordant species. J. Heart Lung Transplant. 16: 758-764.
75. KOIKE, C. et al. 1996. Establishment of a human DAF/HRF20 double transgenic mouse line is not sufficient to suppress hyperacute rejection. Surg. Today 26: 993-998.
76. MAKRIDES, S.C. 1998. Therapeutic inhibition of the complement system. Pharmacol. Rev. 50: 59-87.
77. KRAUS, D., M.E. MEDOF & C. MOLD. 1998. Complement recognition of alternative pathway activators by decay-accelerating factor and factor H. Infect. Immun. 66: 399-405.
78. KOTWAL, G.J. 1997. Microogranisms and their interaction with the immune system. J. Leuk. Biol. 62: 415-429.
79. WANG, G. et al. 1998. Functional differences among multiple isoforms of guinea pig decay-accelerating factor. J. Immunol. 160: 3014-3022.
80. XIA, W. et al. 1992. Prolongation of guinea pig cardiac xenograft survival in rats by soluble human complement receptor type 1. Transplant. Proc. 24: 479-480.
81. PRUITT, S.K. et al. 1994. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 57: 363-370.
82. SUN, Q-Y., G. CHEN, H. GUO, et al. 2003. Prolonged cardiac xenograft survival in guinea pia-to-rat model by a highly active cobra venom factor. Toxicon 42: 257-262.
83. KOTWAL, G.J. & B. MOSS. 1988. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335: 176-178.
84. KOTWAL, G.J., S.N. ISAACS, R. MCKENZIE, et al. 1990. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250: 827-829.
85. ISAACS, S.N., G.J. KOTWAL & B. MOSS. 1992. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc. Natl. Acad. Sci. USA 89: 628-632.
86. AL-MOHANNA, F., R. PARHAR & G.J. KOTWAL. 2001. Vaccinia virus complement control protein is capable of protecting xenoendothelial cells from antibody binding and killing by human complement and cytotoxic cells. Transplantation 71: 796-801.
87. MURTHY, K.H.M., S.A. SMITH, V.K. GANESH, et al. 2001. Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans. Cell 104: 301-311.
88. ANDERSON, J.B., S.A. SMITH, R. VAN WIJK, et al. 2002. Vaccinia virus complement control protein ameliorates hyperacute xenorejection by inhibiting xenoantibody binding. Transplant. Proc. 34: 3277-3281.
89. ANDERSON, J.B., S.A. SMITH & G.J. KOTWAL. 2002. Vaccinia virus complement control protein inhibits hyperacute xenorejection. Transplant. Proc. 34: 1083-1085.
90. KAHN, D., S.A. SMITH & G.J. KOTWAL. 2003. Dose-dependent inhibition of complement in baboons by vaccinia virus complement control protein: implications in xenotransplantation. Transplant. Proc. 35: 1606-1608.
91. SMITH, S.A. et al. 2000. Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as a putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense. J. Virol. 74: 5659-5666.
92. JHA, P., S.A. SMITH, D.E. JUSTUS & G.J. KOTWAL. 2003. Prolonged retention of vaccinia virus complement control protein following ip injection: implications in blocking xenorejection. Transplant. Proc. 35: 3160-3162.
93. WINKLER, M.E., U. MARTIN, M. LOSS, et al. 2000. Porcine endogenous retrovirus is not transmitted in a discordant porcine-to-cynomolgus xenokidney transplantation model with long-term survival of organ recipients. Transplant. Proc. 32: 1162.
94. ALLAN, J.S. 1996. Xenotransplantation at a crossroads: prevention versus progress. Nat. Med. 2: 18-21.
95. BACH, F.H. et al. 1998. Uncertainty in xenotransplantation: Individual benefit versus collective risk. Nat. Med. 4: 141-144.
96. HENEINE, W., A. TIBELL, G.J. SWITZER, et al. 1998. No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet 352: 695-699.
97. SPECKE, V., H.-J. SCHUURMAN, R. PLESKER, et al. 2002. Virus safety in xenotransplantation: first exploratory in vivo studies in small laboratory animals and non-human primates. Transplant. Immunol. 9: 281-288.
98. PARADIS, K. et al. 1999. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. Science 285: 1236-1241.
99. DINSMORE, J.H., C. MANHART, R. RAINERI, et al. 2000. No evidence for infection of human cells with porcine endogenous retrovirus (PERV) after exposure to porcine fetal neuronal cells. Transplantation 70: 1382-1389.
100. SWITZER, W.M. et al. 2001. Lack of cross-species transmission of porcine endogenous retrovirus infection to nonhuman primate recipients of porcine cells, tissues, or organs. Transplantation 71: 959-965.
101. KUDUS, R., J.F. PATZER II, R. LOPEZ, et al. 2002. Clinical and laboratory evaluation of the safety of a bioartificial liver assist device for potential transmission of porcine endogenous retrovirus. Transplantation 73: 420-429.
102. IRGANG, M. et al. 2003. Porcine endogenous retroviruses: no infection in patients treated with a bioreactor based on porcine liver cells. J. Clin. Virol. 28: 141-154.
103. FIEBIG, U., O. STEPHAN, R. KURTH & J. DENNER. 2003. Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses: basis for a vaccine for xenotransplantation? Virology 307: 406-413.